Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.
Saved in:
| Title: | Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. |
|---|---|
| Authors: | Huang W; Genentech Inc, South San Francisco, CA, United States., Stader F; Certara UK Limited, Sheffield, United Kingdom., Chan P; Genentech Inc, South San Francisco, CA, United States., Shemesh CS; Genentech Inc, South San Francisco, CA, United States., Chen Y; Genentech Inc, South San Francisco, CA, United States., Gill KL; Certara UK Limited, Sheffield, United Kingdom., Jones HM; Certara UK Limited, Sheffield, United Kingdom., Li L; Certara UK Limited, Sheffield, United Kingdom., Rossato G; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Wu B; Genentech Inc, South San Francisco, CA, United States., Jin JY; Genentech Inc, South San Francisco, CA, United States., Chanu P; Genentech Inc, South San Francisco, CA, United States. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2022 Sep 26; Vol. 13, pp. 974423. Date of Electronic Publication: 2022 Sep 26 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36225583 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Huang+W%22">Huang W</searchLink>; Genentech Inc, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Stader+F%22">Stader F</searchLink>; Certara UK Limited, Sheffield, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Chan+P%22">Chan P</searchLink>; Genentech Inc, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Shemesh+CS%22">Shemesh CS</searchLink>; Genentech Inc, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Genentech Inc, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Gill+KL%22">Gill KL</searchLink>; Certara UK Limited, Sheffield, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Jones+HM%22">Jones HM</searchLink>; Certara UK Limited, Sheffield, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Li+L%22">Li L</searchLink>; Certara UK Limited, Sheffield, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Rossato+G%22">Rossato G</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Wu+B%22">Wu B</searchLink>; Genentech Inc, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Jin+JY%22">Jin JY</searchLink>; Genentech Inc, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Chanu+P%22">Chanu P</searchLink>; Genentech Inc, South San Francisco, CA, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101548923%22">Frontiers in pharmacology</searchLink> [Front Pharmacol] 2022 Sep 26; Vol. 13, pp. 974423. <i>Date of Electronic Publication: </i>2022 Sep 26 (<i>Print Publication: </i>2022). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media]%22">Frontiers Media] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101548923 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1663-9812 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216639812%22">16639812 </searchLink><i>NLM ISO Abbreviation: </i>Front Pharmacol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36225583 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fphar.2022.974423 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 974423 Titles: – TitleFull: Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Huang W – PersonEntity: Name: NameFull: Stader F – PersonEntity: Name: NameFull: Chan P – PersonEntity: Name: NameFull: Shemesh CS – PersonEntity: Name: NameFull: Chen Y – PersonEntity: Name: NameFull: Gill KL – PersonEntity: Name: NameFull: Jones HM – PersonEntity: Name: NameFull: Li L – PersonEntity: Name: NameFull: Rossato G – PersonEntity: Name: NameFull: Wu B – PersonEntity: Name: NameFull: Jin JY – PersonEntity: Name: NameFull: Chanu P IsPartOfRelationships: – BibEntity: Dates: – D: 26 M: 09 Text: 2022 Sep 26 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 1663-9812 Numbering: – Type: volume Value: 13 Titles: – TitleFull: Frontiers in pharmacology Type: main |
| ResultId | 1 |
